EUVIMEDObjevte EUVIMED
Open access · CC BY-NC 4.0

Prevalence of Cancer Survivors in 2019 Among Patients Diagnosed Between 1975 and 2019: A Population‐Based Study in Japan

Haruka Kudo, Kayo Nakata, Kenji Kishimoto, Toshiki Ikawa, Yoko Iwaki, Yoshihiro Kuwabara, Toshitaka Morishima iD, Isao Miyashiro

Cancer Medicine · 2026-06 · 15 (6)

DOI: 10.1002/cam4.72012 ↗

At a glance

Journal article in Cancer Medicine, published online on 2026-06-04. Written by Haruka Kudo and 7 co-authors. Institution: Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan. Major MEDLINE topics: Neoplasms, Cancer Survivors. 42 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Ministry of Health, Labour and Welfare, Japan Society for the Promotion of Science.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Owing to improved prognosis, cancer survivors are a growing population; however, little is known about their prevalence in Asian countries. This study estimated the prevalence and characteristics of cancer survivors in Japan, including long‐term survivors. Using data from the Osaka Cancer Registry, which covers 8.8 million residents in Osaka Prefecture, Japan, we identified individuals diagnosed with cancer between 1975 and 2019 who were alive in 2019. Cancer prevalence was calculated as the number of patients alive in 2019, stratified by sex, age in 2019, time since diagnosis, and 22 cancer types. National estimates were obtained by applying sex‐ and age‐specific prevalence proportions in Osaka to the Japanese population. In 2019, 461,489 cancer survivors were living in Osaka Prefecture (5.4% of the prefectural population; 5221 per 100,000). Most were older adults, with 83% of males ( n = 188,881) and 70% of females ( n = 163,331) aged ≥ 65 years in 2019. Long‐term survivors (≥ 10 years after diagnosis) comprised 34% of all survivors. These patterns varied across cancer types. Nationally, an estimated 6.9 million individuals (5.5% of the national population) lived after a cancer diagnosis. Based on 44 years of follow‐up data, our findings highlighted a substantial subgroup of cancer survivors requiring long‐term treatment, follow‐up care, and age‐specific support. These findings may provide useful insights for healthcare planning and cancer survivor policies in aging societies.

Subjects

MeSH terms (MEDLINE)

NeoplasmsCancer SurvivorsHumansJapanFemaleMalePrevalenceAgedMiddle AgedAdultRegistriesAged, 80 and overAdolescentYoung AdultChildChild, PreschoolInfantInfant, Newborn

Author keywords

cancer registrycancer survivorspopulation‐based studyprevalence

Authors and institutions

  • Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.

ORCID profiles: Toshitaka Morishima

Funding

  • Ministry of Health, Labour and Welfare
  • Japan Society for the Promotion of Science

Cite

APA

Kudo, H., Nakata, K., Kishimoto, K., Ikawa, T., Iwaki, Y., Kuwabara, Y., Morishima, T., & Miyashiro, I. (2026). Prevalence of Cancer Survivors in 2019 Among Patients Diagnosed Between 1975 and 2019: A Population‐Based Study in Japan. Cancer Medicine, 15(6). https://doi.org/10.1002/cam4.72012

Vancouver

Kudo H, Nakata K, Kishimoto K, Ikawa T, Iwaki Y, Kuwabara Y, et al. Prevalence of Cancer Survivors in 2019 Among Patients Diagnosed Between 1975 and 2019: A Population‐Based Study in Japan. Cancer Medicine. 2026;15(6). doi:10.1002/cam4.72012

BibTeX
@article{Kudo2026,
  author = {Kudo, Haruka and Nakata, Kayo and Kishimoto, Kenji and Ikawa, Toshiki and Iwaki, Yoko and Kuwabara, Yoshihiro and Morishima, Toshitaka and Miyashiro, Isao},
  title = {Prevalence of Cancer Survivors in 2019 Among Patients Diagnosed Between 1975 and 2019: A Population‐Based Study in Japan},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {6},
  doi = {10.1002/cam4.72012}
}
Start for free →